Gilead Sciences

GILD

Market cap $154B

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.

Gilead has successfully launched Yeztugo, the successor to its blockbuster Biktarvy. Gilead expects Yeztugo sales to reach $100 million in Q4, even though it was only approved by the FDA on June 18 last year. Even weak sales of the oncology franchise in Q3 didn't prevent Gilead's EBIT margin from reaching a three-year high of 45.2%.

Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry conference that kicked off on Monday in San Francisco.

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Daniel O'Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication, drug pipeline outlook, impact of AI, and more.

If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DALLAS--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”) today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (“Gilead”) to evaluate OncoNano's ON-BOARD™ encapsulation technology with Gilead's drug candidate. Under the terms of the agreement, OncoNano and Gilead will collaborate to evaluate the stability, selectivity and efficacy of Gilead's drug candidate encapsulated by OncoNano's ON-BOARD technology. “Partnering with Gilead underscores the broad applicabili.

Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.